Projects per year
Search results
-
Active
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Perkins, A. (Primary Chief Investigator (PCI))
6/11/24 → 5/11/26
Project: Research
-
Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management
Mithraprabhu, S. (Primary Chief Investigator (PCI)), Khong, T. (Chief Investigator (CI)), Reynolds, J. (Chief Investigator (CI)), Murray, D. (Chief Investigator (CI)), Shah, J. (Chief Investigator (CI)), Wellard, C. (Chief Investigator (CI)), Spencer, A. (Associate Investigator (AI)), Ross, J. (Associate Investigator (AI)), Perkins, A. (Associate Investigator (AI)), Marks, A. (Associate Investigator (AI)), Beer, H. (Associate Investigator (AI)) & Henderson, M. (Associate Investigator (AI))
1/04/24 → 31/12/26
Project: Research
-
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Perkins, A. (Primary Chief Investigator (PCI))
12/09/23 → 12/09/26
Project: Research
-
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
13/07/23 → 12/07/25
Project: Research
-
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG300) in Patients with Polycythemia Vera
Perkins, A. (Primary Chief Investigator (PCI)) & Malherbe, M. (Project Manager)
18/10/22 → 31/10/25
Project: Research
-
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/ul).
Perkins, A. (Primary Chief Investigator (PCI)), Ma, C. K. K. (Chief Investigator (CI)) & Kennedy, N. (Project Manager)
16/03/21 → 31/12/26
Project: Research
-
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
4/03/21 → 31/12/26
Project: Research
-
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1).
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
12/10/20 → 31/12/25
Project: Research
-
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2).
Perkins, A. (Primary Chief Investigator (PCI)), Kennedy, N. (Project Manager), Chuah, H. (Chief Investigator (CI)), Arbelaez, A. (Chief Investigator (CI)) & Prasad, R. (Chief Investigator (CI))
12/10/20 → 31/12/25
Project: Research
-
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
Perkins, A. (Primary Chief Investigator (PCI))
6/03/20 → 31/12/25
Project: Research
-
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
Perkins, A. (Primary Chief Investigator (PCI)), Leahy, M. F. (Chief Investigator (CI)), Ross, D. M. (Chief Investigator (CI)), Prasad, R. (Chief Investigator (CI)), Kennedy, N. (Project Manager) & Choi, P. (Chief Investigator (CI))
5/02/20 → 31/12/25
Project: Research
-
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (KRT-232-101)
Perkins, A. (Primary Chief Investigator (PCI)), Ross, D. M. (Chief Investigator (CI)), Kennedy, N. (Project Manager), Yeh, P. (Partner Investigator (PI)) & Wright, M. (Chief Investigator (CI))
20/01/20 → 31/12/25
Project: Research
-
A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera (KRT-232-102)
Perkins, A. (Primary Chief Investigator (PCI)), Burbury, K. L. (Chief Investigator (CI)) & Kennedy, N. (Project Manager)
20/01/20 → 31/12/25
Project: Research
-
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of Fedratinib compared to best available therapy in subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and previously treated with ruxolitinib (The FREEDOM 2 trial)
Perkins, A. (Primary Chief Investigator (PCI)) & Kennedy, N. (Project Manager)
Bristol-Myers Squibb (Australia)
16/12/19 → 31/12/25
Project: Research